In a filing, Blueprint Medicines Corp revealed its CHIEF FINANCIAL OFFICER Landsittel Michael unloaded Company’s shares for reported $0.47 million on Mar 28 ’24. In the deal valued at $95.00 per share,5,000 shares were sold. As a result of this transaction, Landsittel Michael now holds 47,286 shares worth roughly $4.36 million.
Then, Albers Jeffrey W. sold 25,073 shares, generating $2,188,264 in total proceeds. Upon selling the shares at $87.28, the Director now owns 176,050 shares.
Before that, Landsittel Michael sold 13,734 shares. Blueprint Medicines Corp shares valued at $1,205,606 were divested by the CHIEF FINANCIAL OFFICER at a price of $87.78 per share. As a result of the transaction, Landsittel Michael now holds 47,286 shares, worth roughly $4.36 million.
Oppenheimer upgraded its Blueprint Medicines Corp [BPMC] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in late August has reiterated a ‘”a Buy”‘ rating for it. Wells Fargo also remained covering BPMC and has increased its forecast on July 31, 2023 with a “an Overweight” recommendation from previously “an Equal weight” rating. SVB Securities revised its rating on June 05, 2023. It rated BPMC as “an Underperform” which previously was an “a Market perform”.
Price Performance Review of BPMC
On Tuesday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 0.72% to $92.20. Over the last five days, the stock has gained 0.70%. Blueprint Medicines Corp shares have fallen nearly -0.04% since the year began. Nevertheless, the stocks have risen 110.36% over the past one year. While a 52-week high of $101.00 was reached on 02/28/24, a 52-week low of $41.75 was recorded on 02/14/24. SMA at 50 days reached $87.63, while 200 days put it at $68.55. A total of 0.71 million shares were traded, compared to the trading of 0.7 million shares in the previous session.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 91.05, which if violated will result in even more drops to 89.90. On the upside, there is a resistance level at 93.64. A further resistance level may holdings at 95.08. The Relative Strength Index (RSI) on the 14-day chart is 53.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.43, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.38%. Stochastics %K at 57.31% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on Mar 15, 2024, growing by 0.52 million shares to a total of 5.15 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 4.63 million shares. There was a rise of 10.1%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 11.31% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.2.
